Qiu's Cervical Prescription inhibit the invasion and growth of cervical cancer through LncRNA ATB/miR-126 pathway

Yingping Zhu; Yang Lv; Haili Yao; Zhilei Chen; Wenjuan Yang; Chuntao Tian; Weiyi Yang; Mingyang Li; Qingge Jia; Liangping Wang

doi:10.1016/j.prp.2024.155784

Qiu's Cervical Prescription inhibit the invasion and growth of cervical cancer through LncRNA ATB/miR-126 pathway

Pathol Res Pract. 2024 Dec 20:266:155784. doi: 10.1016/j.prp.2024.155784. Online ahead of print.

Authors

Yingping Zhu¹, Yang Lv², Haili Yao³, Zhilei Chen⁴, Wenjuan Yang⁴, Chuntao Tian⁵, Weiyi Yang⁶, Mingyang Li⁷, Qingge Jia⁸, Liangping Wang⁹

Affiliations

¹ Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
² Department of Pathology, No. 942 Hospital of the Chinese People's Liberation Army Logistic Support Force, Yinchuan, China.
³ Department of Central Sterile Supply, Navy Qingdao Special Service Rehabilitation Center, Qingdao, China.
⁴ First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
⁵ Department of Oncology, Sanmenxia Central Hospital, Sanmenxia, China.
⁶ Department of Neurology, Xi'an Daxing Hospital, Xi'an, China.
⁷ State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China. Electronic address: limingyang1108@sina.com.
⁸ Department of Reproductive Medicine, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China. Electronic address: 361400283@qq.com.
⁹ Center for Reproductive Medicine, Department of Reproductive Endocrinology，Zhejiang Provincial People's Hospital, Hangzhou, China. Electronic address: wangliangping419@163.com.

PMID: 39709873
DOI: 10.1016/j.prp.2024.155784

Abstract

Background: Cervical cancer (CC) is one of the most deadly cancers in women, its current treatments still result in poor outcomes and developing the novel targets and therapeutic strategies are urgently needed. Qiu's Cervical Prescription (QCP) is one of the traditional Chinese medicines used in the treatment of cervical cancer in China. Although its curative effect is remarkable, the internal mechanism of its treatment is still poorly understood. Recent studies have shown that LncRNA ATB might be used as a new proliferation marker for cancer diagnosis and prognosis. This study aimed to investigate the possible mechanism of action of QCP in the treatment of cervical cancer.

Methods: The functional assays of migration and invasion in vitro using transwell assays and wound healing assays was performed to confirm the pro-carcinogenic effect of LncRNA ATB, and the changes of migration and invasion of HeLa cells were observed after treatment with QCP containing drug serum. The changes in tumor volume, general condition of transplanted tumor-bearing mice and expression of LncRNA ATB pathway-related proteins were detected by qPCR, Western blotting and HE staining after treatment with the QCP.

Results: We induced LncRNA ATB knockdown and overexpression in cervical cancer cell lines and detected the biological behavior changes in vitro. Furthermore, we established murine models using stable LncRNA ATB-shRNA HeLa cells or overexpression LncRNA ATB cells or normal Hela cells with QCP to evaluate how suppression of LncRNA ATB affects tumor growth.

Conclusion: We showed that potential mechanism of QCP in the treatment of cervical cancer may be through inhibition of the LncRNA ATB/miR-126/TGFβ1 signaling axis. In conclusion, QCP may be a promising approach for the treatment of CC.

Keywords: Cervical cancer; LncRNA ATB; MiR-126; Qiu’s Cervical Prescription.